Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon Alpha 2a for HBsAg Loss in Chronic Hepatitis B
NCT01172392Phase 3Unknown
- Sponsor
- ANRS
- Start
- Jan 2011
- Primary completion
- Jun 2015
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2a in Chronic Hepatitis B (CHB) (2 arms), sponsored by ANRS. Primary endpoint: HBsAg negativation at week 96. Status: unknown.
02
Drugs
peginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01172392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01172392.